Special Issue "MYC Networks"
Deadline for manuscript submissions: closed (28 February 2017).
Dr. Daitoku Sakamuro
Associate Professor, Department of Biochemistry and Molecular Biology, Medical College of Georgia and Georgia Cancer Center, Augusta University, 1410 Laney Walker Blvd., Augusta, GA 30912, USA
Website | E-Mail
Phone: +1 706 (721) 1018
Interests: c-MYC; E2F1; BIN1; PARP1; RB1; transcriptional corepressor; oncogenes; tumor suppressors; genomic instability; serum starvation; apoptosis (including anoikis); cancer chemosensitivity
Regardless of its comprehensive and in-depth study over more than three decades, the c-MYC protein is still biologically an enigmatic topic of research. The protein plays a central role in various cellular functions, including cell-cycle progression, de-differentiation, genomic instability, apoptosis, and metabolism, but also in recently-emerged research areas, such as pluripotency in iPS and cancer stem cells, epigenetic gene regulation, chromatin remodeling, RNA splicing, and immune response. As a bona fide oncogenic transcription factor, c-MYC has also been recognized as a fascinating anticancer therapeutic target. However, the precise mechanism(s) through which c-MYC properly exerts its divergent cellular functions remain obscure. It is significant to better understand direct and indirect regulatory/effector molecules of c-MYC pathways and protein components in c-MYC-containing high-molecular-weight complexes: It may provide conceptually a new anticancer drug design target in cancers addicted to c-MYC.
In this Special Issue, we would like to invite submission of original research or review articles on any topic related to the “c-MYC Networks”, through which we hope to explore new horizons of the thrilling functions of c-MYC in normal tissue development and tumorigenesis.
We look forward to receiving your contributions.
Dr. Daitoku Sakamuro
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- gene transactivation vs. transrepression
- protein translation
- cell-cycle progression and cellular transformation
- apoptosis, autophagy, and anoikis
- genomic instability vs. cancer chemoresistance
- cancer metabolism
- c-MYC-induced de-differentiation and iPS formation
- RNA splicing
- chromatin remodeling and epigenetics
- MYC family and human cancer
- MYC and cancer immunotherapy